Model organism

BenchSci Extends Impact on Drug Discovery With Addition of AI-Assisted Animal Model Selection

Retrieved on: 
Wednesday, July 28, 2021

BenchSci enables scientists to make more informed and precise animal model selections by providing evidence of successful utilization in experiments similar to their own.

Key Points: 
  • BenchSci enables scientists to make more informed and precise animal model selections by providing evidence of successful utilization in experiments similar to their own.
  • "We're proud to be introducing animal models to the BenchSci platform as we continue to focus on helping scientists accelerate preclinical research," says Casandra Mangroo, BenchSci's SVP of Product and Science.
  • Scientists will have the information they need to select the most appropriate animal model to advance their experiments."
  • BenchSci's animal model database includes:
    The addition of animal models to the platform is one more way that BenchSci is becoming a complete resource for all aspects of decision-making in experimental design.

New Partnership Announced by ingenious targeting laboratory and Shanghai Model Organisms Center to Distribute Catalog Humanized Mouse Models

Retrieved on: 
Thursday, June 3, 2021

RONKONKOMA, N.Y. and SHANGHAI, June 3, 2021 /PRNewswire-PRWeb/ -- ingenious targeting laboratory, a leading provider of custom animal models for in vivo studies, and Shanghai Model Organisms Center, "SMOC," a major supplier of laboratory rodents and services, announced a partnership that grants rights for ingenious targeting laboratory to distribute SMOC's validated off-the-shelf mouse models in North America and Europe.

Key Points: 
  • RONKONKOMA, N.Y. and SHANGHAI, June 3, 2021 /PRNewswire-PRWeb/ -- ingenious targeting laboratory, a leading provider of custom animal models for in vivo studies, and Shanghai Model Organisms Center, "SMOC," a major supplier of laboratory rodents and services, announced a partnership that grants rights for ingenious targeting laboratory to distribute SMOC's validated off-the-shelf mouse models in North America and Europe.
  • These strains will be sold by ingenious targeting laboratory, as well as many other immune checkpoint humanized mouse strains.
  • In addition, SMOC is known as a "one-stop shop," as their service offerings include custom mouse models, catalog mouse models, breeding services, and phenotypic analysis.
  • About Shanghai Model Organisms Center, Inc. (SMOC)
    Founded in 2000, Shanghai Model Organisms Center, Inc. (SMOC) is a leading company in China, providing high-quality animal models and related services to global researchers.

Passage Bio Announces Pre-Clinical Data Presentation at Annual ASGCT Meeting

Retrieved on: 
Tuesday, May 11, 2021

\xe2\x80\x9cOne of the major challenges in developing treatments for MLD has been the limited availability of mouse models and scarcity of phenotype in existing models.

Key Points: 
  • \xe2\x80\x9cOne of the major challenges in developing treatments for MLD has been the limited availability of mouse models and scarcity of phenotype in existing models.
  • This model reproduces important aspects of human leukodystrophy neuropathology, including key biomarkers.
  • As we work with speed and tenacity, we are always mindful of patients who may be able to benefit from our therapies.
  • Passage Bio undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.\n'

What Animal Alliance of Canada would like everyone to know about COVID-19 Vaccine Testing

Retrieved on: 
Tuesday, April 21, 2020

This acceptance of a 10% predictive rate using animal models is in stark contrast with the85-90% predictive rate using modern vitro technologies.

Key Points: 
  • This acceptance of a 10% predictive rate using animal models is in stark contrast with the85-90% predictive rate using modern vitro technologies.
  • Liz White, Director of Animal Alliance of Canada, a national animal advocacyorganization, states, "What most people do not know is that mice are resistant to the COVID-19 virus.
  • Researchers then use the mice to test a vaccine in order tomeet regulatory requirements before starting clinical trials on humans.
  • Consequently, we need to discuss and challenge testing on animal models when we should be using human relevant models.

Insights into the In-vitro Toxicology Testing Market by Technology, Method, Application, End Use, Region & Segment Forecasts to 2027 - ResearchAndMarkets.com

Retrieved on: 
Monday, March 16, 2020

The "In-vitro Toxicology Testing Market Size, Share & Trends Analysis Report By Technology (Cell Culture, High Throughput), By Method, By Application, By End Use, By Region, And Segment Forecasts, 2020 - 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "In-vitro Toxicology Testing Market Size, Share & Trends Analysis Report By Technology (Cell Culture, High Throughput), By Method, By Application, By End Use, By Region, And Segment Forecasts, 2020 - 2027" report has been added to ResearchAndMarkets.com's offering.
  • The global in-vitro toxicology testing market size is anticipated to reach USD 30.9 billion by 2027 and is projected to register a CAGR of 9.2% over the forecast period according to this report.
  • The new paradigm shift in toxicity testing of animal models toward computational methods such as silico models to interpret toxicity pathway data, drives the demand for in-vitro toxicology testing.
  • Several governments are taking measures to minimize animal-based test models, forming conducive government policies, and providing funds to support in-vitro models.

$30+ Billion Worldwide In-vitro Toxicology Testing Market (2020 to 2027) - Rise in Government Funding is a Driver

Retrieved on: 
Friday, February 28, 2020

The global in-vitro toxicology testing market size is anticipated to reach USD 30.9 billion by 2027 and is projected to register a CAGR of 9.2% over the forecast period according to this report.

Key Points: 
  • The global in-vitro toxicology testing market size is anticipated to reach USD 30.9 billion by 2027 and is projected to register a CAGR of 9.2% over the forecast period according to this report.
  • The new paradigm shift in toxicity testing of animal models toward computational methods such as silico models to interpret toxicity pathway data, drives the demand for in-vitro toxicology testing.
  • Several governments are taking measures to minimize animal-based test models, forming conducive government policies, and providing funds to support in-vitro models.
  • This has enabled scientists to access vast information for toxicity profiling, thereby spurring revenue generation in this market.

AxoSim Licenses Revolutionary Mini-Brain Technology from Johns Hopkins University Enabling the Use of Human Data to Speed New Drug Research

Retrieved on: 
Thursday, May 30, 2019

Mini-Brain technology enables scientists to study key brain functions, test new therapies and screen for toxic substances in human rather than animal models at an early stage of research.

Key Points: 
  • Mini-Brain technology enables scientists to study key brain functions, test new therapies and screen for toxic substances in human rather than animal models at an early stage of research.
  • The recent costly clinical trial failures of new Alzheimer's drugs highlight the need for better ways to test drug candidates much earlier in development.
  • The Mini-Brain technology was developed to replace inaccurate animal testing with accurate, predictive models of the human brain.
  • Related Nerve-on-a-Chip technology developed at AxoSim has been shown to achieve research milestones at a fraction of the time and cost of conventional animal testing.

Vium and 3Scan Collaborate To Transform Scientific Discovery With Breakthrough Disease Models To Improve Preclinical Research

Retrieved on: 
Wednesday, September 5, 2018

The companies provide drug discovery and disease researchers with improved insights into disease biology and progression for these challenging diseases with high unmet clinical needs.

Key Points: 
  • The companies provide drug discovery and disease researchers with improved insights into disease biology and progression for these challenging diseases with high unmet clinical needs.
  • With this information, we can better understand the disease biology, which is at the foundation for building better in vivo mouse models.
  • Improved disease models that better translate to humans gets us closer to helping people combat disease."
  • The Vium Digital Vivarium, Vium Cloud, and online Research Suite empower scientists to optimize advances in bioengineered research models in ways previously not possible.

Global In-vitro Toxicology Testing Market Report: Size, Share & Trends Analysis 2014-2025

Retrieved on: 
Friday, August 31, 2018

The "In-vitro Toxicology Testing Market Size, Share & Trends Analysis Report By Technology, By Method (Cellular Assay, Biochemical Assay, In Silica, Ex-vivo), By Application, By End-Use, By Region, And Segment Forecasts, 2018 - 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "In-vitro Toxicology Testing Market Size, Share & Trends Analysis Report By Technology, By Method (Cellular Assay, Biochemical Assay, In Silica, Ex-vivo), By Application, By End-Use, By Region, And Segment Forecasts, 2018 - 2025" report has been added to ResearchAndMarkets.com's offering.
  • The global in-vitro toxicology testing market size is expected to reach USD 26.98 billion by 2025, progressing at a CAGR of 11.4% during the forecast period.
  • Technological advancements in computational biology along with introduction of novel efficient algorithms help in conduct of efficient stimulation of in-silico animal models.
  • This, in turn, has significantly curtailed the need for animal models for clinical studies, thereby providing a fillip to the market.

Animal Models to Gain Ground in Light of Their Efficacy in Testing of Vaccines & Therapies for Viral Epidemics, Unveils Fact.MR

Retrieved on: 
Thursday, August 23, 2018

This is expected to be a key growth influencer of the animal model market.

Key Points: 
  • This is expected to be a key growth influencer of the animal model market.
  • A recent report compiled by Fact.MR projects the animal model market to register an impressive CAGR of over 6.0% during the period of forecast, 2017 to 2026.
  • The healthcare sector is seen harnessing animal models, owing to which the demand for animal model is surging in the healthcare sector.
  • Effectiveness of animal models in developing and testing efficacy of vaccines and therapies, prior to their use in human candidates, is likely to augur well for growth of the animal models market.